Cytotoxic anticancer agents and renal impairment study: The challenge remains

Journal of Clinical Oncology

Volumn 24, Issue 4, 2006, Pages 533-536

  Rahman, Atiqur ^a   White, Robert M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BICARBONATE; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYTOTOXIC AGENT; FOLIC ACID; HOMOCYSTEINE; METHOTREXATE; PEMETREXED; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADVANCED CANCER; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG INDUCED DISEASE; DRUG RESEARCH; EDITORIAL; FATIGUE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; LOADING DRUG DOSE; MESOTHELIOMA; MONOTHERAPY; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION; CHRONIC KIDNEY FAILURE; DRUG ADMINISTRATION; DRUG EFFECT; METABOLISM; NEOPLASM; NOTE; PATHOPHYSIOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; DRUG ADMINISTRATION SCHEDULE; FOLIC ACID; GLOMERULAR FILTRATION RATE; GLUTAMATES; GUANINE; HUMANS; KIDNEY FAILURE, CHRONIC; NEOPLASMS; VITAMIN B 12;

EID: 33644837945     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.8299     Document Type: Editorial

References (23)

1. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Taxol, 2000: http://www.fda.gov/cder/foi/label/2000/20262S36LBL.PDF
2. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Taxotere, 2005: http://www.fda.gov/cder/foi/label/2005/020449s033lbl. pdf
3. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Eloxatin: http://www.fda.gov/cder/foi/label/2005/021759lbl.pdf
4. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Velcade: http://www.fda.gov/cder/foi/label/2005/021602s006lbl.pdf
5. Veslemes M, Antoniou D, Georgatou N, et al: Phase II study of cisplatin-combined schedules as second-line chemotherapy in patients with non-small-cell lung cancer. Anticancer Res 25:2991-2996, 2005
6. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Zometa: http://www.fda.gov/cder/foi/label/2005/021223s011lbl.pdf
7. Glasmacher A, von Lilienfeld-Toal M, Schulte S, et al: An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 5:17-23, 2005
8. Mita AC, Sweeney CJ, Baker SD, et al: A phase 1 and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24:552-562, 2006
9. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Alimta: http://www.fda.gov/cder/foi/label/2004/021677lbl.pdf
10. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644, 2003
11. Cohen MH, Johnson JR, Wang YC, et al: FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10:363-368, 2005
12. 12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21:1556-1561, 2003
13. Hazarika M, White RM, Booth BP, et al: Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11:982-992, 2005
14. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Ellance: http://www.fda.gov/cder/foi/label/2005/50778s008lbl.pdf
15. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Hycamtin: http://www.fda.gov/cder/foi/label/2003/ 20671slr012_hycamtin_lbl.pdf
16. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Vidaza: http://www.fda.gov/cder/foi/label/2004/050794lbl.pdf
17. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Xeloda: http://www.fda.gov/cder/foi/label/2005/020896s0161lbl.pdf
18. Calvert AH, Egorin MJ: Carboplatin dosing formulae: Gender bias and the use of creatinine-based methodologies. Eur J Cancer 38:11-16, 2002
19. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Paraplatin: http://www.fda.gov/cder/foi/label/2004/ 20452scs001_paraplatin_lbl.pdf
20. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Platinol: http://www.fda.gov/cder/foi/label/1993/018057lbl.pdf
21. Christensen ML, Rivera GK, Crom WR, et al: Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia. J Clin Oncol 6:797-801, 1988
22. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Methotrexate: http://www.fda.gov/cder/foi/label/2004/011719lbl.pdf
23. Tarella C, Bono D, Zanni M, et al: Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemia. Contrib Nephrol 147:93-104, 2005